



GAVI Alliance

Annual Progress Report **2013**

Submitted by

The Government of
Bangladesh

Reporting on year: **2013**

Requesting for support year: **2015**

Date of submission: **15/05/2014**

Deadline for submission: 22/05/2014

Please submit the APR **2013** using the online platform <https://AppsPortal.gavialliance.org/PDExtranet>

Enquiries to: apr@gavialliance.org or representatives of a GAVI Alliance partner. The documents can be shared with GAVI Alliance partners, collaborators and general public. The APR and attachments must be submitted in English, French, Spanish, or Russian.

Note: *You are encouraged to use previous APRs and approved Proposals for GAVI support as reference documents. The electronic copy of the previous APRs and approved proposals for GAVI support are available at <http://www.gavialliance.org/country/>*

The GAVI Secretariat is unable to return submitted documents and attachments to countries. Unless otherwise specified, documents will be shared with the GAVI Alliance partners and the general public.

**GAVI ALLIANCE
GRANT TERMS AND CONDITIONS**

FUNDING USED SOLELY FOR APPROVED PROGRAMMES

The applicant country ("Country") confirms that all funding provided by the GAVI Alliance will be used and applied for the sole purpose of fulfilling the programme(s) described in the Country's application. Any significant change from the approved programme(s) must be reviewed and approved in advance by the GAVI Alliance. All funding decisions for the application are made at the discretion of the GAVI Alliance Board and are subject to the Independent Review Committee (IRC) and its processes and the availability of funds.

AMENDMENT TO THE APPLICATION

The Country will notify the GAVI Alliance in its Annual Progress Report (APR) if it wishes to propose any change to the programme(s) description in its application. The GAVI Alliance will document any change approved by the GAVI Alliance, and the Country's application will be amended.

RETURN OF FUNDS

The Country agrees to reimburse to the GAVI Alliance all funding amounts that are not used for the programme(s) described in its application. The country's reimbursement must be in US dollars and be provided, unless otherwise decided by the GAVI Alliance, within sixty (60) days after the Country receives the GAVI Alliance's request for a reimbursement and be paid to the account or accounts as directed by the GAVI Alliance.

SUSPENSION/ TERMINATION

The GAVI Alliance may suspend all or part of its funding to the Country if it has reason to suspect that funds have been used for purpose other than for the programmes described in the Country's application, or any GAVI Alliance-approved amendment to the application. The GAVI Alliance retains the right to terminate its support to the Country for the programmes described in its application if a misuse of GAVI Alliance funds is confirmed.

ANTICORRUPTION

The Country confirms that funds provided by the GAVI Alliance shall not be offered by the Country to any third person, nor will the Country seek in connection with its application any gift, payment or benefit directly or indirectly that could be construed as an illegal or corrupt practice.

AUDITS AND RECORDS

The Country will conduct annual financial audits, and share these with the GAVI Alliance, as requested. The GAVI Alliance reserves the right, on its own or through an agent, to perform audits or other financial management assessment to ensure the accountability of funds disbursed to the Country.

The Country will maintain accurate accounting records documenting how GAVI Alliance funds are used. The Country will maintain its accounting records in accordance with its government-approved accounting standards for at least three years after the date of last disbursement of GAVI Alliance funds. If there is any claims of misuse of funds, Country will maintain such records until the audit findings are final. The Country agrees not to assert any documentary privilege against the GAVI Alliance in connection with any audit.

CONFIRMATION OF LEGAL VALIDITY

The Country and the signatories for the Country confirm that its application, and APR, are accurate and correct and form legally binding obligations on the Country, under the Country's law, to perform the programmes described in its application, as amended, if applicable, in the APR.

CONFIRMATION OF COMPLIANCE WITH THE GAVI ALLIANCE TRANSPARANCY AND ACCOUNTABILITY POLICY

The Country confirms that it is familiar with the GAVI Alliance Transparency and Accountability Policy (TAP) and complies with the requirements therein.

USE OF COMMERCIAL BANK ACCOUNTS

The Country is responsible for undertaking the necessary due diligence on all commercial banks used to manage GAVI cash-based support. The Country confirms that it will take all responsibility for replenishing GAVI cash support lost due to bank insolvency, fraud or any other unforeseen event.

ARBITRATION

Any dispute between the Country and the GAVI Alliance arising out of or relating to its application that is not settled amicably within a reasonable period of time, will be submitted to arbitration at the request of either the GAVI Alliance or the Country. The arbitration will be conducted in accordance with the then-current UNCITRAL Arbitration Rules. The parties agree to be bound by the arbitration award, as the final adjudication of any such dispute. The place of arbitration will be Geneva, Switzerland. The languages of the arbitration will be English or French.

For any dispute for which the amount at issue is US\$ 100,000 or less, there will be one arbitrator appointed by the GAVI Alliance. For any dispute for which the amount at issue is greater than US \$100,000 there will be three arbitrators appointed as follows: The GAVI Alliance and the Country will each appoint one arbitrator, and the two arbitrators so appointed will jointly appoint a third arbitrator who shall be the chairperson.

The GAVI Alliance will not be liable to the country for any claim or loss relating to the programmes described in the application, including without limitation, any financial loss, reliance claims, any harm to property, or personal injury or death. Country is solely responsible for all aspects of managing and implementing the programmes described in its application.

By filling this APR the country will inform GAVI about:

Accomplishments using GAVI resources in the past year

Important problems that were encountered and how the country has tried to overcome them

Meeting accountability needs concerning the use of GAVI disbursed funding and in-country arrangements with development partners

Requesting more funds that had been approved in previous application for ISS/NVS/HSS, but have not yet been released

How GAVI can make the APR more user-friendly while meeting GAVI's principles to be accountable and transparent.

1. Application Specification

Reporting on year: 2013

Requesting for support year: 2015

1.1. NVS & INS support

Type of Support	Current Vaccine	Preferred presentation	Active until
Routine New Vaccines Support	DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	2015
Routine New Vaccines Support	Measles second dose, 10 dose(s) per vial, LYOPHILISED	Measles second dose, 10 dose(s) per vial, LYOPHILISED	2016
Routine New Vaccines Support	Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID	Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID	2016

DTP-HepB-Hib (Pentavalent) vaccine: Based on current country preferences the vaccine is available through UNICEF in fully liquid 1 and 10 dose vial presentations and in a 2 dose-2 vials liquid/lyophilised formulation, to be used in a three-dose schedule. Other presentations are also WHO pre-qualified, and a full list can be viewed on the [WHO website](#), but availability would need to be confirmed specifically.

1.2. Programme extension

No NVS support eligible to extension this year

1.3. ISS, HSS, CSO support

Type of Support	Reporting fund utilisation in 2013	Request for Approval of	Eligible For 2013 ISS reward
ISS	No	next tranche: N/A	N/A
HSS	Yes	next tranche of HSS Grant Yes	N/A
VIG	No	Not applicable	N/A
COS	Yes	Not applicable	N/A

VIG: Vaccine Introduction Grant; COS: Campaign Operational Support

1.4. Previous Monitoring IRC Report

APR Monitoring IRC Report for year 2012 is available [here](#).

2. Signatures

2.1. Government Signatures Page for all GAVI Support (ISS, INS, NVS, HSS, CSO)

By signing this page, the Government of **Bangladesh** hereby attests the validity of the information provided in the report, including all attachments, annexes, financial statements and/or audit reports. The Government further confirms that vaccines, supplies, and funding were used in accordance with the GAVI Alliance Standard Grant Terms and Conditions as stated in this Annual Progress Report (APR).

For the Government of **Bangladesh**

Please note that this APR will not be reviewed or approved by the Independent Review Committee (IRC) without the signatures of both the Minister of Health & Minister Finance or their delegated authority.

Minister of Health (or delegated authority)		Minister of Finance (or delegated authority)	
Name	Mr. M. M. Neazuddin, Secretary, MoH&FW	Name	Shahabuddin Ahmed, Additional Secretary, Ministry of Finance
Date		Date	
Signature		Signature	

This report has been compiled by (these persons may be contacted in case the GAVI Secretariat has queries on this document):

Full name	Position	Telephone	Email
Dr. Shafiqur Rahman	Programme Manager-EPI & Surveillance, DGHS, MOH&FW	+880-2-8821910-13	shafiquer56@yahoo.com
Dr. Jayantha Liyanage	Medical Officer-EPI, IVD, WHO, Bangladesh	+880-2-9899540 Ext. 27309	liyanagej@searo.who.int
Dr. Jucy Merina Adhikari	Immunization Specialist, Health Section, UNICEF, Bangladesh	+880-2-8852266 Ext. 7144	jmadhikari@unicef.org
Dr. Ashek Ahammed Shahid Reza	Deputy Programme Manager-EPI, DGHS, MOH&FW	+880-2-8821910-13	aasreza@yahoo.com

2.2. ICC signatures page

If the country is reporting on Immunisation Services (ISS), Injection Safety (INS) and/or New and Under-Used Vaccines (NVS) supports

In some countries, HSCC and ICC committees are merged. Please fill-in each section where information is appropriate and upload in the attached documents section the signatures twice, one for HSCC signatures and one for ICC signatures

The GAVI Alliance Transparency and Accountability Policy (TAP) is an integral part of GAVI Alliance monitoring of country performance. By signing this form the ICC members confirm that the funds received from the GAVI Alliance have been used for purposes stated within the approved application and managed in a transparent manner, in accordance with government rules and regulations for financial management.

2.2.1. ICC report endorsement

We, the undersigned members of the immunisation Inter-Agency Coordinating Committee (ICC), endorse this report. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Name/Title	Agency/Organization	Signature	Date
------------	---------------------	-----------	------

Md. Akhter Hossain, Joint Secretary	Local Government Division, Ministry of Local Government, Rural Development & Co- operatives		
Dr. Kaosar Afsana, Director, BRAC Health Program	BRAC		
Peggy Thorpe, First Secretary, Development	DFATD		
Gregory Adams, Acting Director, Population, Health & Nutrition	USAID		
Dr. Bushra Binte Alam, Senior Health Specialist, Health Sector Development Programme	World Bank		
Dr. Lianne Kuppens, Chief, Health Section	UNICEF		
DR. Khaled Hassan, WHO Representative to Bangladesh	WHO		
Dr. Shehlina Ahmed, Health Advisor	DFID		
PDG Salim Reza, Chairman	Rotary International		
Mr. Kenji Tanaka, Representative	JICA		

ICC may wish to send informal comments to: apr@gavialliance.org

All comments will be treated confidentially

Comments from Partners:

N/A

Comments from the Regional Working Group:

N/A

2.3. HSCC signatures page

We, the undersigned members of the National Health Sector Coordinating Committee (HSCC), N/A, endorse this report on the Health Systems Strengthening Programme. Signature of endorsement of this document

does not imply any financial (or legal) commitment on the part of the partner agency or individual.

The GAVI Alliance Transparency and Accountability Policy is an integral part of GAVI Alliance monitoring of country performance. By signing this form the HSCC members confirm that the funds received from the GAVI Alliance have been used for purposes stated within the approved application and managed in a transparent manner, in accordance with government rules and regulations for financial management. Furthermore, the HSCC confirms that the content of this report has been based upon accurate and verifiable financial reporting.

Name/Title	Agency/Organization	Signature	Date
NA	NA		

HSCC may wish to send informal comments to: apr@gavialliance.org

All comments will be treated confidentially

Comments from Partners:

NA

Comments from the Regional Working Group:

NA

2.4. Signatures Page for GAVI Alliance CSO Support (Type A & B)

Bangladesh is not reporting on CSO (Type A & B) fund utilisation in 2014

3. Table of Contents

This APR reports on Bangladesh's activities between January – December 2013 and specifies the requests for the period of January – December 2015

Sections

[1. Application Specification](#)

[1.1. NVS & INS support](#)

[1.2. Programme extension](#)

[1.3. ISS, HSS, CSO support](#)

[1.4. Previous Monitoring IRC Report](#)

[2. Signatures](#)

[2.1. Government Signatures Page for all GAVI Support \(ISS, INS, NVS, HSS, CSO\)](#)

[2.2. ICC signatures page](#)

[2.2.1. ICC report endorsement](#)

[2.3. HSCC signatures page](#)

[2.4. Signatures Page for GAVI Alliance CSO Support \(Type A & B\)](#)

[3. Table of Contents](#)

[4. Baseline & annual targets](#)

[5. General Programme Management Component](#)

[5.1. Updated baseline and annual targets](#)

[5.2. Immunisation achievements in 2013](#)

[5.3. Monitoring the Implementation of GAVI Gender Policy](#)

[5.4. Data assessments](#)

[5.5. Overall Expenditures and Financing for Immunisation](#)

[5.6. Financial Management](#)

[5.7. Interagency Coordinating Committee \(ICC\)](#)

[5.8. Priority actions in 2014 to 2015](#)

[5.9. Progress of transition plan for injection safety](#)

[6. Immunisation Services Support \(ISS\)](#)

[6.1. Report on the use of ISS funds in 2013](#)

[6.2. Detailed expenditure of ISS funds during the 2013 calendar year](#)

[6.3. Request for ISS reward](#)

[7. New and Under-used Vaccines Support \(NVS\)](#)

[7.1. Receipt of new & under-used vaccines for 2013 vaccine programme](#)

[7.2. Introduction of a New Vaccine in 2013](#)

[7.3. New Vaccine Introduction Grant lump sums 2013](#)

[7.3.1. Financial Management Reporting](#)

[7.3.2. Programmatic Reporting](#)

[7.4. Report on country co-financing in 2013](#)

[7.5. Vaccine Management \(EVSM/VMA/EVM\)](#)

[7.6. Monitoring GAVI Support for Preventive Campaigns in 2013](#)

[7.7. Change of vaccine presentation](#)

[7.8. Renewal of multi-year vaccines support for those countries whose current support is ending in 2014](#)

[7.9. Request for continued support for vaccines for 2015 vaccination programme](#)

[7.10. Weighted average prices of supply and related freight cost](#)

[7.11. Calculation of requirements](#)

[8. Injection Safety Support \(INS\)](#)

[9. Health Systems Strengthening Support \(HSS\)](#)

[9.1. Report on the use of HSS funds in 2013 and request of a new tranche](#)

[9.2. Progress on HSS activities in the 2013 fiscal year](#)

[9.3. General overview of targets achieved](#)

[9.4. Programme implementation in 2013](#)

[9.5. Planned HSS activities for 2014](#)

[9.6. Planned HSS activities for 2015](#)

[9.7. Revised indicators in case of reprogramming](#)

[9.8. Other sources of funding for HSS](#)

[9.9. Reporting on the HSS grant](#)

[10. Strengthened Involvement of Civil Society Organisations \(CSOs\) : Type A and Type B](#)

[10.1. TYPE A: Support to strengthen coordination and representation of CSOs](#)

[10.2. TYPE B: Support for CSOs to help implement the GAVI HSS proposal or cMYP](#)

[11. Comments from ICC/HSCC Chairs](#)

[12. Annexes](#)

[12.1. Annex 1 – Terms of reference ISS](#)

[12.2. Annex 2 – Example income & expenditure ISS](#)

[12.3. Annex 3 – Terms of reference HSS](#)

[12.4. Annex 4 – Example income & expenditure HSS](#)

[12.5. Annex 5 – Terms of reference CSO](#)

[12.6. Annex 6 – Example income & expenditure CSO](#)

[13. Attachments](#)

4. Baseline & annual targets

Countries are encouraged to aim for realistic and appropriate wastage rates informed by an analysis of their own wastage data. In the absence of country-specific data, countries may use indicative maximum wastage values as shown on the **Wastage Rate Table** available in the guidelines. Please note the benchmark wastage rate for 10ds pentavalent which is available.

Number	Achievements as per JRF		Targets (preferred presentation)					
	2013		2014		2015		2016	
	Original approved target according to Decision Letter	Reported	Original approved target according to Decision Letter	Current estimation	Previous estimates in 2013	Current estimation	Previous estimates in 2013	Current estimation
Total births	3,478,236	3,478,236	3,525,888	3,525,888	3,574,192	3,574,192	3,623,159	3,623,159
Total infants' deaths	149,564	149,564	151,613	151,613	153,690	153,690	155,796	155,796
Total surviving infants	3328672	3,328,672	3,374,275	3,374,275	3,420,502	3,420,502	3,467,363	3,467,363
Total pregnant women	3,478,236	3,478,236	3,525,888	3,525,888	3,574,192	3,574,192	3,623,159	3,623,159
Number of infants vaccinated (to be vaccinated) with BCG	3,408,671	3,697,234	3,455,370	3,455,370	3,502,708	3,502,708	3,550,696	3,550,696
BCG coverage	98 %	106 %	98 %	98 %	98 %	98 %	98 %	98 %
Number of infants vaccinated (to be vaccinated) with OPV3	3,095,665	3,587,089	3,138,075	3,138,075	3,181,067	3,181,067	3,224,647	3,224,647
OPV3 coverage	93 %	108 %	93 %	93 %	93 %	93 %	93 %	93 %
Number of infants vaccinated (to be vaccinated) with DTP1	3,162,238	3,650,721	3,205,561	3,205,561	3,249,477	3,249,477	3,293,995	3,293,995
Number of infants vaccinated (to be vaccinated) with DTP3	3,095,665	3,586,574	3,138,075	3,138,075	3,181,067	3,181,067	3,224,647	3,224,647
DTP3 coverage	93 %	108 %	93 %	93 %	93 %	93 %	93 %	93 %
Wastage[1] rate in base-year and planned thereafter (%) for DTP	0	0	0	0	0	0	0	0
Wastage[1] factor in base-year and planned thereafter for DTP	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Number of infants vaccinated (to be vaccinated) with 1 dose of DTP-HepB-Hib	3,640,007	3,650,721	3,205,561	3,205,561	3,249,477	3,249,477		
Number of infants vaccinated (to be vaccinated) with 3 dose of DTP-HepB-Hib	3,640,007	3,586,574	3,205,561	3,138,075	3,181,067	3,181,067		
DTP-HepB-Hib coverage	109 %	108 %	95 %	93 %	93 %	93 %	0 %	0 %
Wastage[1] rate in base-year and planned thereafter (%)	5	1	5	5	5	5		
Wastage[1] factor in base-year and planned thereafter (%)	1.05	1.01	1.05	1.05	1.05	1.05	1	1
Maximum wastage rate value for DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	5 %	5 %	5 %	5 %	5 %	5 %	5 %	5 %
Number of infants vaccinated (to be vaccinated) with 1 dose of Pneumococcal (PCV10)		0	6,996,860	3,205,561		0		0

Number of infants vaccinated (to be vaccinated) with 3 dose of Pneumococcal (PCV10)		0	6,996,860	3,138,075		0		0
Pneumococcal (PCV10) coverage		0 %	207 %	93 %		0 %		0 %
Wastage ^[1] rate in base-year and planned thereafter (%)		0	10	1		0		0
Wastage ^[1] factor in base-year and planned thereafter (%)		1	1.11	1.01		1		1
Maximum wastage rate value for Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID		0 %	10 %	10 %	10 %	0 %	10 %	0 %
Number of infants vaccinated (to be vaccinated) with 1st dose of Measles	3,448,428	3,604,266	6,411,121	3,205,561	3,420,502	3,420,502	3,467,363	3,467,363
Number of infants vaccinated (to be vaccinated) with 2nd dose of Measles	3,328,672	3,284,229	3,374,274	3,205,561	3,420,502	3,420,502	3,467,363	3,467,363
Measles coverage	100 %	99 %	100 %	95 %	100 %	100 %	100 %	100 %
Wastage ^[1] rate in base-year and planned thereafter (%) {0}	50	40	50	1	40	40	40	40
Wastage ^[1] factor in base-year and planned thereafter (%)	2	1.67	2	1.01	1.67	1.67	1.67	1.67
Maximum wastage rate value for Measles second dose, 10 dose(s) per vial, LYOPHILISED	40.00 %	40.00 %	40.00 %	40.00 %	40.00 %	40.00 %	40.00 %	40.00 %
Pregnant women vaccinated with TT+	3,478,236	1,753,606	3,525,888	3,525,888	3,574,192	3,574,192	3,623,159	3,623,159
TT+ coverage	100 %	50 %	100 %	100 %	100 %	100 %	100 %	100 %
Vit A supplement to mothers within 6 weeks from delivery	2,546,556	2,587,447	0	0	0	0	0	0
Vit A supplement to infants after 6 months	2,264,511	20,506,057	0	0	0	0	0	0
Annual DTP Drop out rate [(DTP1 – DTP3) / DTP1] x 100	2 %	2 %	2 %	2 %	2 %	2 %	2 %	2 %

** Number of infants vaccinated out of total surviving infants

*** Indicate total number of children vaccinated with either DTP alone or combined

**** Number of pregnant women vaccinated with TT+ out of total pregnant women

1 The formula to calculate a vaccine wastage rate (in percentage): $[(A - B) / A] \times 100$. Whereby: A = the number of doses distributed for use according to the supply records with correction for stock balance at the end of the supply period; B = the number of vaccinations with the same vaccine in the same period.

5. General Programme Management Component

5.1. Updated baseline and annual targets

Note: Fill in the table in section 4 Baseline and Annual Targets before you continue

The numbers for 2013 must be consistent with those that the country reported in the **WHO/UNICEF Joint Reporting Form (JRF) for 2013**. The numbers for 2014 - 2015 in Table 4 Baseline and Annual Targets should be consistent with those that the country provided to GAVI in previous APR or in new application for GAVI support or in cMYP.

In fields below, please provide justification and reasons for those numbers that in this APR are different from the referenced ones:

- Justification for any changes in **births**

N/A

- Justification for any changes in **surviving infants**

N/A

- Justification for any changes in targets by vaccine. **Please note that targets in excess of 10% of previous years' achievements will need to be justified.**

N/A

- Justification for any changes in **wastage by vaccine**

N/A

5.2. Immunisation achievements in 2013

5.2.1. Please comment on the achievements of immunisation programme against targets (as stated in last year APR), the key major activities conducted and the challenges faced in 2013 and how these were addressed:

Vaccination coverage increased in terms of quantity and quality (reduced dropout rate and invalid doses), reduced number of district having fully vaccination coverage of below 80%.

Key major activities conducted: Intensified routine immunization activities in low performing districts - microplan developed using RED strategy, updated the list of hard to reach areas, listing & vaccination of eligible children for MSD, listing of dropout & left out children of under one year for vaccination, conducted regular monthly review meetings, conducted quarterly micro plan review meeting, conducted data quality self-assessment, training of trainers for mid level managers on EPI and training for monitoring EPI activities, computerized data management training to the key personnel of sub district level, computerized data monitoring system implemented in two low performing districts, conducted quarterly coordination meeting with Multi-sectoral partners. Conducted EVM self assessment, AEFI management & VPDs refreshers training.

Challenges: Urban immunization coverage due to high migration of population and total number of Measles cases in 2013 is 237 cases.

5.2.2. If targets were not reached, please comment on reasons for not reaching the targets:

Not Applicable

5.3. Monitoring the Implementation of GAVI Gender Policy

5.3.1. At any point in the past five years, were sex-disaggregated data on DTP3 coverage available in your country from administrative data sources and/or surveys? **yes, available**

If yes, please report the latest data available and the year that it is from.

Data Source	Reference Year for Estimate	DTP3 Coverage Estimate	
		Boys	Girls
Coverage Evaluation Survey.	2009	86%	85%

Coverage Evaluation Survey	2010	89%	88%
Coverage Evaluation Survey	2011	89%	90%
Coverage Evaluation Survey	2013	92.3%	91.7%

5.3.2. How have any discrepancies in reaching boys versus girls been addressed programmatically?

There is no significant gender discrimination in vaccination coverage between boys and girls.

5.3.3. If no sex-disaggregated data are available at the moment, do you plan in the future to collect sex-disaggregated coverage estimates? **No**

5.3.4. How have any gender-related barriers to accessing and delivering immunisation services (eg, mothers not being empowered to access services, the sex of service providers, etc) been addressed programmatically? (For more information on gender-related barriers, please see GAVI's factsheet on gender and immunisation, which can be found on <http://www.gavialliance.org/about/mission/gender/>)

Not Applicable

5.4. Data assessments

5.4.1. Please comment on any discrepancies between immunisation coverage data from different sources (for example, if survey data indicate coverage levels that are different than those measured through the administrative data system, or if the WHO/UNICEF Estimate of National Immunisation Coverage and the official country estimate are different)

Variation observed between survey and administrative coverage data.

* Please note that the WHO UNICEF estimates for 2013 will only be available in July 2014 and can have retrospective changes on the time series.

5.4.2. Have any assessments of administrative data systems been conducted from 2012 to the present? **Yes**

If Yes, please describe the assessment(s) and when they took place.

Data Quality Self Assessment (DQSA) regularly conducted by Surveillance Medical Officers, District Maternal Child Health and Immunization Officers (DMCH&IOs) and local level Health Managers

5.4.3. Please describe any major activities undertaken to improve administrative data systems from 2011 to the present.

Computerized data entry and electronic reporting system established in all districts and city corporations, regular monthly review of tally sheet and administrative data conducted at districts & sub-districts level, quarterly multi -sectoral review meeting conducted to improve administrative data reporting system at divisional level.

5.4.4. Please describe any plans that are in place, or will be put into place, to make further improvements to administrative data systems.

Computerized data entry system introduced in 102 upazila (sub district) of 19 districts. Continuous supervision and monitoring conducted by the 1st line and 2nd line supervisors. SMOs and DMCH&IOs regularly monitored data management system and provided technical assistance.

5.5. Overall Expenditures and Financing for Immunisation

The purpose of **Table 5.5a** is to guide GAVI understanding of the broad trends in immunisation programme expenditures and financial flows. Please fill the table using US\$.

Exchange rate used	1 US\$ = 77.4	Enter the rate only; Please do not enter local currency name
---------------------------	---------------	--

Table 5.5a: Overall Expenditure and Financing for Immunisation from all sources (Government and donors) in US\$

Expenditure by category	Expenditure Year 2013	Source of funding						
		Country	GAVI	UNICEF	WHO	World Bank/Pool Fund	N/A	N/A

Traditional Vaccines*	12,611,516	0	0	2,342,187	0	10,269,329	0	0
New and underused Vaccines**	32,259,804	0	29,431,943	0	0	2,827,861	0	0
Injection supplies (both AD syringes and syringes other than ADs)	471,964	334,625	137,339	0	0	0	0	0
Cold Chain equipment	2,807,062	0	0	1,098,764	1,212,523	495,775	0	0
Personnel	665,000	0	0	0	665,000	0	0	0
Other routine recurrent costs	3,954,685	1,632,222	93,162	1,879,511	349,790	0	0	0
Other Capital Costs	0	0	0	0	0	0	0	0
Campaigns costs	1,916,925	1,485,788	0	274,590	156,547	0	0	0
Campaign Vaccine Cost		0	0	0	0	7,560,000	0	0
Total Expenditures for Immunisation	54,686,956							
Total Government Health		3,452,635	29,662,444	5,595,052	2,383,860	21,152,965	0	0

* Traditional vaccines: BCG, DTP, OPV (or IPV), Measles 1st dose (or the combined MR, MMR), TT. Some countries will also include HepB and Hib vaccines in this row, if these vaccines were introduced without GAVI support.

5.5.1. If there are no government funding allocated to traditional vaccines, please state the reasons and plans for the expected sources of funding for 2014 and 2015

NA

5.6. Financial Management

5.6.1. Has a GAVI Financial Management Assessment (FMA) been conducted prior to, or during the 2012 calendar year? **No, not implemented at all**

If **Yes**, briefly describe progress against requirements and conditions which were agreed in any Aide Memoire concluded between GAVI and the country in the table below:

Action plan from Aide Mémoire	Implemented?
N/A	No

If the above table shows the action plan from Aide Memoire has been fully or partially implemented, briefly state exactly what has been implemented

Not applicable

If none has been implemented, briefly state below why those requirements and conditions were not met.

Not applicable

5.7. Interagency Coordinating Committee (ICC)

How many times did the ICC meet in 2013? **3**

Please attach the minutes (**Document n° 4**) from the ICC meeting in 2014 endorsing this report.

List the key concerns or recommendations, if any, made by the ICC on sections [5.1 Updated baseline and annual targets](#) to [5.5 Overall Expenditures and Financing for Immunisation](#)

Not Applicable

Are any Civil Society Organisations members of the ICC? **Yes**

If **Yes**, which ones?

List CSO member organisations:
Rotary International

5.8. Priority actions in 2014 to 2015

What are the country's main objectives and priority actions for its EPI programme for 2014 to 2015

Objective 1: Improve Immunization coverage among children under one and child bearing age women, namely

- Fully Vaccinated Children coverage at least 84% in 2014 and 85% in 2015 in every district
- TT 5 coverage at least 65% in 2014 and 70% in 2015 in every district

Key Activities:

- Implement RED strategy in every district, giving special emphasis to the 32 low performing districts and 4 City corporation
- Strengthen regular supportive supervision at each level
- Strengthen coordination with development partners and local NGOs/GoB
- Strengthening of coverage and VPDs and AEFI surveillance system
- Ensure sufficient, timely and potent vaccines and quality injection devices available at all level with no stock out
- Conduct regular monthly review meeting at district and sub-district level to provide feedback, on-job-training and to improve capacity of health workers
- Improved cold chain capacity at all level and ensure cold chain maintenance
- Periodical review of the National EPI program performance at each level and take timely and appropriate measures accordingly.

Objective 2. Maintain polio free status

- Intensify implementing Acute Flaccid Paralysis (AFP) Surveillance,
- Conducting supplementary OPV vaccination (NIDs/SNIDs), mop-up OPV campaigns, and maintaining high routine OPV coverage to maintain the polio free status in the country.
- IPV introduction in 2014 at least one dose
- Ensure completion of phase-1 laboratory containment of wild polio virus and sabin virus

Objective 3. Maintain maternal and neonatal tetanus elimination status

- Maintain high coverage of TT5 among childbearing age women
- Maintain high TT protection at birth
- Intensify current NT surveillance

Objective 4. Achieve national level 95% measles coverage and reaching elimination status by 2016

- Maintain high MCV1 and MSD coverage among infants with special emphasis to the low coverage districts
- Intensify measles surveillance
- Conduct nationwide MR campaign

Objective: 5: Achieve 95% Rubella coverage and reaching rubella and CRS control

- Maintain high MR coverage among infants
- Intensify measles surveillance and sentinel surveillance of CRS
- Conduct nationwide MR campaign

Objective: 6. Prevention of diseases protected by new and underused vaccines

- Introduce Pneumococcal vaccine in to the national EPI programme
- Introduce IPV in to the national EPI programme
- Introduce HPV as district demonstration project
- Identify priorities for vaccine introduction based on epidemiological evidence
- Ensure the future financial sustainability

Objective 7. Ensure safe injection practices and waste disposal

- Implementation on national plan on sharp and waste management
- Strengthen AEFI surveillance system
- Ensure injection safety

5.9. Progress of transition plan for injection safety

For all countries, please report on progress of transition plan for injection safety

Please report what types of syringes are used and the funding sources of Injection Safety material in 2013

Vaccine	Types of syringe used in 2013 routine EPI	Funding sources of 2013
BCG	AD Syringes	GOB
Measles	AD Syringes	GAVI
TT	AD Syringes	GOB
DTP-containing vaccine	AD Syringes	GAVI & GOB
Measles-Rubella vaccine (Routine)	AD Syringes	GOB

Does the country have an injection safety policy/plan? **Yes**

If Yes: Have you encountered any obstacles during the implementation of this injection safety policy/plan?

If No: When will the country develop the injection safety policy/plan? (Please report in box below)

No

Please explain in 2013 how sharps waste is being disposed of, problems encountered, etc.

There are two types recommended practice for sharp waste disposal of routine EPI: incineration and open pit burning.

The incineration is confined in the major urban areas where incinerator is available and for most of the rural areas the choice is open pit burning. In future proper shape waste management will be a big challenged with incorporating NUV in routine programme by government and need GAVI support in this area.

6. Immunisation Services Support (ISS)

6.1. Report on the use of ISS funds in 2013

Bangladesh is not reporting on Immunisation Services Support (ISS) fund utilisation in 2013

6.2. Detailed expenditure of ISS funds during the 2013 calendar year

Bangladesh is not reporting on Immunisation Services Support (ISS) fund utilisation in 2013

6.3. Request for ISS reward

Request for ISS reward achievement in Bangladesh is not applicable for 2013

7. New and Under-used Vaccines Support (NVS)

7.1. Receipt of new & under-used vaccines for 2013 vaccine programme

7.1.1. Did you receive the approved amount of vaccine doses for 2013 Immunisation Programme that GAVI communicated to you in its Decision Letter (DL)? Fill-in table below

Table 7.1: Vaccines received for 2013 vaccinations against approvals for 2013

	[A]	[B]		
Vaccine type	Total doses for 2013 in Decision Letter	Total doses received by 31 December 2013	Total doses of postponed deliveries in 2013	Did the country experience any stockouts at any level in 2013?
DTP-HepB-Hib	11,082,550	10,482,550	600,000	No
Measles	7,818,500	7,818,500	0	No
Pneumococcal (PCV10)		0	0	Not selected

**Please also include any deliveries from the previous year received against this Decision Letter*

If values in [A] and [B] are different, specify:

- What are the main problems encountered? (Lower vaccine utilisation than anticipated due to delayed new vaccine introduction or lower coverage? Delay in shipments? Stock-outs? Excessive stocks? Problems with cold chain? Doses discarded because VVM changed colour or because of the expiry date? ...)

No problem is encountered related to vaccine shipments during the reporting period.

- What actions have you taken to improve the vaccine management, e.g. such as adjusting the plan for vaccine shipments? (in the country and with UNICEF Supply Division)

GAVI would also appreciate feedback from countries on feasibility and interest of selecting and being shipped multiple Pentavalent vaccine presentations (1 dose and 10 dose vials) so as to optimise wastage, coverage and cost.

The country is using one dose Pentavalent vaccine presentation and is experienced very low wastage rate

If **Yes** for any vaccine in **Table 7.1**, please describe the duration, reason and impact of stock-out, including if the stock-out was at the central, regional, district or at lower facility level.

N/A

7.2. Introduction of a New Vaccine in 2013

7.2.1. If you have been approved by GAVI to introduce a new vaccine in 2013, please refer to the vaccine introduction plan in the proposal approved and report on achievements:

DTP-HepB-Hib, 1 dose(s) per vial, LIQUID		
Phased introduction	No	
Nationwide introduction	No	
The time and scale of introduction was as planned in the proposal? If No, Why ?	No	NA

Measles second dose, 10 dose(s) per vial, LYOPHILISED		
Phased introduction	No	
Nationwide introduction	No	
The time and scale of introduction was as planned in the proposal? If No, Why ?	No	NA

Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID		
Phased introduction	No	
Nationwide introduction	No	
The time and scale of introduction was as planned in the proposal? If No, Why ?	No	NA

7.2.2. When is the Post Introduction Evaluation (PIE) planned? **March 2012**

If your country conducted a PIE in the past two years, please attach relevant reports and provide a summary on the status of implementation of the recommendations following the PIE. (Document N° 9)

NA

7.2.3. Adverse Event Following Immunization (AEFI)

Is there a national dedicated vaccine pharmacovigilance capacity? **Yes**

Is there a national AEFI expert review committee? **Yes**

Does the country have an institutional development plan for vaccine safety? **Yes**

Is the country sharing its vaccine safety data with other countries? **No**

Is the country sharing its vaccine safety data with other countries? **No**

Does your country have a risk communication strategy with preparedness plans to address vaccine crises? **Yes**

7.2.4. Surveillance

Does your country conduct sentinel surveillance for:

a. rotavirus diarrhea? **Yes**

b. pediatric bacterial meningitis or pneumococcal or meningococcal disease? **Yes**

Does your country conduct special studies around:

a. rotavirus diarrhea? **Yes**

b. pediatric bacterial meningitis or pneumococcal or meningococcal disease? **Yes**

If so, does the National Immunization Technical Advisory Group (NITAG) or the Inter-Agency Coordinating Committee (ICC) regularly review the sentinel surveillance and special studies data to provide recommendations on the data generated and how to further improve data quality? **No**

Do you plan to use these sentinel surveillance and/or special studies data to monitor and evaluate the impact of vaccine introduction and use? **Yes**

Please describe the results of surveillance/special studies and inputs of the NITAG/ICC:

NA

7.3. New Vaccine Introduction Grant lump sums 2013

7.3.1. Financial Management Reporting

	Amount US\$	Amount local currency
Funds received during 2013 (A)	0	0
Remaining funds (carry over) from 2012 (B)	92,358	7,148,531
Total funds available in 2013 (C=A+B)	92,358	7,148,531
Total Expenditures in 2013 (D)	88,380	6,840,579
Balance carried over to 2014 (E=C-D)	3,978	307,952

Detailed expenditure of New Vaccines Introduction Grant funds during the 2013 calendar year

Please attach a detailed financial statement for the use of New Vaccines Introduction Grant funds in the 2013 calendar year (Document No 10,11) . Terms of reference for this financial statement are available in **Annexe 1** Financial statements should be signed by the Finance Manager of the EPI Program and and the EPI Manager, or by the Permanent Secretary of Ministry of Health

7.3.2. Programmatic Reporting

Please report on major activities that have been undertaken in relation to the introduction of a new vaccine, using the GAVI New Vaccine Introduction Grant

NA

Please describe any problem encountered and solutions in the implementation of the planned activities

NA

Please describe the activities that will be undertaken with any remaining balance of funds for 2014 onwards

NA

7.4. Report on country co-financing in 2013

Table 7.4 : Five questions on country co-financing

Co-Financed Payments	Q.1: What were the actual co-financed amounts and doses in 2013?	
	Total Amount in US\$	Total Amount in Doses
Awarded Vaccine #1: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	2,827,861	1,036,750
Awarded Vaccine #2: Measles second dose, 10 dose(s) per vial, LYOPHILISED	0	0
Awarded Vaccine #3: Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID	0	0

	Q.2: Which were the amounts of funding for country co-financing in reporting year 2013 from the following sources?	
Government	N/A	
Donor	Pool Fund (World Bank)	
Other	N/A	
	Q.3: Did you procure related injections supplies for the co-financing vaccines? What were the amounts in US\$ and supplies?	
Co-Financed Payments	Total Amount in US\$	Total Amount in Doses
Awarded Vaccine #1: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	0	0
Awarded Vaccine #2: Measles second dose, 10 dose(s) per vial, LYOPHILISED	0	0
Awarded Vaccine #3: Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID	0	0
	Q.4: When do you intend to transfer funds for co-financing in 2015 and what is the expected source of this funding	
Schedule of Co-Financing Payments	Proposed Payment Date for 2015	Source of funding
Awarded Vaccine #1: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID		
Awarded Vaccine #2: Measles second dose, 10 dose(s) per vial, LYOPHILISED		
Awarded Vaccine #3: Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID		
	Q.5: Please state any Technical Assistance needs for developing financial sustainability strategies, mobilising funding for immunization, including for co-financing	
	NA	

If the country is in default, please describe and explain the steps the country is planning to take to meet its co-financing requirements. For more information, please see the GAVI Alliance Default Policy:

<http://www.gavialliance.org/about/governance/programme-policies/co-financing/>

NA

Is support from GAVI, in form of new and under-used vaccines and injection supplies, reported in the national health sector budget? **Yes**

7.5. Vaccine Management (EVSM/VMA/EVM)

Please note that Effective Vaccine Store Management (EVSM) and Vaccine Management Assessment (VMA) tools have been replaced by an integrated Effective Vaccine Management (EVM) tool. The information on EVM tool can be found at http://www.who.int/immunization_delivery/systems_policy/logistics/en/index6.html

It is mandatory for the countries to conduct an EVM prior to an application for introduction of a new vaccine. This assessment concludes with an Improvement Plan including activities and timelines whose progress report is reported with annual report. The EVM assessment is valid for a period of three years.

When was the latest Effective Vaccine Management (EVM) or an alternative assessment (EVSM/VMA) carried out? **April 2011**

Please attach:

- (a) EVM assessment (**Document No 12**)

(b) Improvement plan after EVM (**Document No 13**)

(c) Progress report on the activities implemented during the year and status of implementation of recommendations from the Improvement Plan (**Document No 14**)

Progress report on EVM/VMA/EVSM Improvement Plan' is a mandatory requirement

Are there any changes in the Improvement plan, with reasons? **No**

If yes, provide details

N/A

When is the next Effective Vaccine Management (EVM) assessment planned? **July 2014**

7.6. Monitoring GAVI Support for Preventive Campaigns in 2013

Bangladesh does not report on NVS Preventive campaign

7.7. Change of vaccine presentation

Bangladesh does not require to change any of the vaccine presentation(s) for future years.

7.8. Renewal of multi-year vaccines support for those countries whose current support is ending in 2014

Renewal of multi-year vaccines support for Bangladesh is not available in 2014

7.9. Request for continued support for vaccines for 2015 vaccination programme

In order to request NVS support for 2015 vaccination do the following

Confirm here below that your request for 2015 vaccines support is as per [7.11 Calculation of requirements](#)

Yes

If you don't confirm, please explain

N/A

7.10. Weighted average prices of supply and related freight cost

Table 7.10.1: Commodities Cost

Estimated prices of supply are not disclosed

Table 7.10.2: Freight Cost

Vaccine Antigens	VaccineTypes	No Threshold	200,000\$		250,000\$	
			<=	>	<=	>
DTP-HepB	HEPBHIB	2.00 %				
HPV bivalent	HPV	3.50 %				
HPV quadrivalent	HPV	3.50 %				
Measles second dose	MEASLES	14.00 %				
Meningococcal type A	MENINACONJUGATE	10.20 %				
MR	MR	13.20 %				
Pneumococcal (PCV10)	PNEUMO	3.00 %				
Pneumococcal (PCV13)	PNEUMO	6.00 %				
Rotavirus	ROTA	5.00 %				
Yellow Fever	YF	7.80 %				

Vaccine Antigens	VaccineTypes	500,000\$		2,000,000\$	
		<=	>	<=	>
DTP-HepB	HEPBHIB				
DTP-HepB-Hib	HEPBHIB	25.50 %	6.40 %		
HPV bivalent	HPV				
HPV quadrivalent	HPV				
Measles second dose	MEASLES				
Meningococcal type A	MENINACONJUGATE				
MR	MR				
Pneumococcal (PCV10)	PNEUMO				
Pneumococcal (PCV13)	PNEUMO				
Rotavirus	ROTA				
Yellow Fever	YF				

7.11. Calculation of requirements

Table 7.11.1: Specifications for DTP-HepB-Hib, 1 dose(s) per vial, LIQUID

ID	Source		2013	2014	2015	TOTAL
Number of surviving infants	Table 4	#	3,328,672	3,374,275	3,420,502	10,123,449
Number of children to be vaccinated with the first dose	Table 4	#	3,640,007	3,205,561	3,249,477	10,095,045
Number of children to be vaccinated with the third dose	Table 4	#	3,640,007	3,205,561	3,181,067	10,026,635

	Immunisation coverage with the third dose	Table 4	%	109.35 %	95.00 %	93.00 %	
	Number of doses per child	Parameter	#	3	3	3	
	Estimated vaccine wastage factor	Table 4	#	1.05	1.05	1.05	
	Vaccine stock on 31st December 2013 * (see explanation footnote)		#	7,629,000			
	Vaccine stock on 1 January 2014 ** (see explanation footnote)		#	7,629,000			
	Number of doses per vial	Parameter	#		1	1	
	AD syringes required	Parameter	#		Yes	Yes	
	Reconstitution syringes required	Parameter	#		No	No	
	Safety boxes required	Parameter	#		Yes	Yes	
cc	Country co-financing per dose	Co-financing table	\$		0.20	0.20	
ca	AD syringe price per unit	Table 7.10.1	\$		0.0450	0.0450	
cr	Reconstitution syringe price per unit	Table 7.10.1	\$		0	0	
cs	Safety box price per unit	Table 7.10.1	\$		0.0050	0.0050	
fv	Freight cost as % of vaccines value	Table 7.10.2	%		6.40 %	6.40 %	
fd	Freight cost as % of devices value	Parameter	%		0.00 %	0.00 %	

* Vaccine stock on 31st December 2012: Countries are asked to report their total closing stock as of 31st December of the reporting year.

** Countries are requested to provide their opening stock for 1st January 2014; if there is a difference between the stock on 31st December 2013 and 1st January 2014, please explain why in the box below.

NA

For pentavalent vaccines, GAVI applies a benchmark of 4.5 months of buffer + operational stocks. Countries should state their buffer + operational stock requirements when different from the benchmark up to a maximum of 6 months. For support on how to calculate the buffer and operational stock levels, please contact WHO or UNICEF. By default, a buffer + operational stock of 4.5 months is pre-selected.

Not defined

Co-financing tables for DTP-HepB-Hib, 1 dose(s) per vial, LIQUID

Co-financing group	Low
--------------------	-----

	2013	2014	2015
Minimum co-financing	0.20	0.20	0.20
Recommended co-financing as per APR 2012			0.20
Your co-financing	0.20	0.20	0.20

Table 7.11.2: Estimated GAVI support and country co-financing (GAVI support)

		2014	2015
Number of vaccine doses	#	8,670,600	10,360,400

Number of AD syringes	#	10,040,800	12,082,000
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	110,450	132,925
Total value to be co-financed by GAVI	\$	18,211,500	22,029,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2014	2015
Number of vaccine doses	#	938,300	1,105,900
Number of AD syringes	#	0	0
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	0	0
Total value to be co-financed by the Country	\$	1,922,000	2,293,500

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 1 dose(s) per vial, LIQUID (part 1)

	Formula	2013	2014			
			Total	Government	GAVI	
A	Country co-finance	V	0.00 %	9.76 %		
B	Number of children to be vaccinated with the first dose	Table 4	3,640,007	3,205,561	313,013	2,892,548
B1	Number of children to be vaccinated with the third dose	Table 4	3,640,007	3,205,561	313,013	2,892,548
C	Number of doses per child	Vaccine parameter (schedule)	3	3		
D	Number of doses needed	$B + B1 + \text{Target for the 2nd dose } ((B - 0.41 \times (B - B1)))$	10,920,021	9,616,683	939,038	8,677,645
E	Estimated vaccine wastage factor	Table 4	1.05	1.05		
F	Number of doses needed including wastage	$D \times E$		10,097,518	985,990	9,111,528
G	Vaccines buffer stock	$((D - D \text{ of previous year}) \times 0.375) + (((D \times E - D) - (D \text{ of previous year} \times E \text{ of previous year} - D \text{ of previous year})) \times 0.375)$		- 488,751	- 47,724	- 441,027
H	Stock to be deducted	$H1 - F \text{ of previous year} \times 0.375$				
H1	Calculated opening stock	$H2 (2014) + H3 (2014) - F (2014)$				
H2	Reported stock on January 1st	Table 7.11.1	3,250,000	7,629,000		
H3	Shipment plan	UNICEF shipment report		4,800,000		
I	Total vaccine doses needed	$\text{Round up}((F + G - H) / \text{vaccine package size}) \times \text{vaccine package size}$		9,608,800	938,268	8,670,532
J	Number of doses per vial	Vaccine Parameter		1		
K	Number of AD syringes (+ 10% wastage) needed	$(D + G - H) \times 1.10$		10,040,726	0	10,040,726
L	Reconstitution syringes (+ 10% wastage) needed	$(I / J) \times 1.10$		0	0	0
M	Total of safety boxes (+ 10% of extra need) needed	$(K + L) / 100 \times 1.10$		110,448	0	110,448
N	Cost of vaccines needed	$I \times \text{vaccine price per dose (g)}$		18,496,940	1,806,166	16,690,774
O	Cost of AD syringes needed	$K \times \text{AD syringe price per unit (ca)}$		451,833	0	451,833
P	Cost of reconstitution syringes needed	$L \times \text{reconstitution price per unit (cr)}$		0	0	0
Q	Cost of safety boxes needed	$M \times \text{safety box price per unit (cs)}$		553	0	553
R	Freight cost for vaccines needed	$N \times \text{freight cost as \% of vaccines value (fv)}$		1,183,805	115,595	1,068,210
S	Freight cost for devices needed	$(O+P+Q) \times \text{freight cost as \% of devices value (fd)}$		0	0	0
T	Total fund needed	$(N+O+P+Q+R+S)$		20,133,131	1,921,760	18,211,371
U	Total country co-financing	$I \times \text{country co-financing per dose (cc)}$		1,921,760		
V	Country co-financing % of GAVI supported proportion	$U / (N + R)$		9.76 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 1 dose(s) per vial, LIQUID (part 2)

	Formula	2015			
		Total	Government	GAVI	
A	Country co-finance	V	9.64 %		
B	Number of children to be vaccinated with the first dose	Table 4	3,249,477	313,394	2,936,083
B1	Number of children to be vaccinated with the third dose	Table 4	3,181,067	306,796	2,874,271
C	Number of doses per child	Vaccine parameter (schedule)	3		
D	Number of doses needed	$B + B1 + \text{Target for the 2nd dose } ((B - 0.41 \times (B - B1)))$	9,651,973	930,878	8,721,095
E	Estimated vaccine wastage factor	Table 4	1.05		
F	Number of doses needed including wastage	$D \times E$	10,134,572	977,422	9,157,150
G	Vaccines buffer stock	$((D - D \text{ of previous year}) \times 0.375) + (((D \times E - D) - (D \text{ of previous year} \times E \text{ of previous year} - D \text{ of previous year})) \times 0.375)$	13,896	1,341	12,555
H	Stock to be deducted	$H1 - F \text{ of previous year} \times 0.375$	- 1,317,706	- 127,085	- 1,190,621
H1	Calculated opening stock	$H2 (2014) + H3 (2014) - F (2014)$	2,431,396	234,495	2,196,901
H2	Reported stock on January 1st	Table 7.11.1			
H3	Shipment plan	UNICEF shipment report			
I	Total vaccine doses needed	$\text{Round up}((F + G - H) / \text{vaccine package size}) \times \text{vaccine package size}$	11,466,200	1,105,850	10,360,350
J	Number of doses per vial	Vaccine Parameter	1		
K	Number of AD syringes (+ 10% wastage) needed	$(D + G - H) \times 1.10$	12,081,932	0	12,081,932
L	Reconstitution syringes (+ 10% wastage) needed	$(I / J) \times 1.10$	0	0	0
M	Total of safety boxes (+ 10% of extra need) needed	$(K + L) / 100 \times 1.10$	132,902	0	132,902
N	Cost of vaccines needed	$I \times \text{vaccine price per dose (g)}$	22,347,624	2,155,301	20,192,323
O	Cost of AD syringes needed	$K \times \text{AD syringe price per unit (ca)}$	543,687	0	543,687
P	Cost of reconstitution syringes needed	$L \times \text{reconstitution price per unit (cr)}$	0	0	0
Q	Cost of safety boxes needed	$M \times \text{safety box price per unit (cs)}$	665	0	665
R	Freight cost for vaccines needed	$N \times \text{freight cost as of \% of vaccines value (fv)}$	1,430,248	137,940	1,292,308
S	Freight cost for devices needed	$(O+P+Q) \times \text{freight cost as \% of devices value (fd)}$	0	0	0
T	Total fund needed	$(N+O+P+Q+R+S)$	24,322,224	2,293,240	22,028,984
U	Total country co-financing	$I \times \text{country co-financing per dose (cc)}$	2,293,240		
V	Country co-financing % of GAVI supported proportion	$U / (N + R)$	9.64 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

The calculated stock which is the stock level estimated by the end of year is negative. A negative calculated stock means that the consumption of the buffer stock would be needed to reach your planned target. Please explain the main reason(s) for replenishment of buffer stocks, such as higher than expected coverage, open vial wastage, other.

NA

The calculated stock which is the stock level estimated by the end of year is negative. A negative calculated stock means that the consumption of the buffer stock would be needed to reach your planned target. Please explain the main reason(s) for replenishment of buffer stocks, such as higher than expected coverage, open vial wastage, other.

Table 7.11.1: Specifications for Measles second dose, 10 dose(s) per vial, LYOPHILISED

ID	Source		2013	2014	2015	2016	TOTAL	
	Number of surviving infants	Table 4	#	3,328,672	3,374,275	3,420,502	3,467,363	13,590,812
	Number of children to be vaccinated with the first dose	Table 4	#	3,448,428	6,411,121	3,420,502	3,467,363	16,747,414
	Number of children to be vaccinated with the second dose	Table 4	#	3,328,672	3,374,274	3,420,502	3,467,363	13,590,811
	Immunisation coverage with the second dose	Table 4	%	100.00 %	100.00 %	100.00 %	100.00 %	
	Number of doses per child	Parameter	#	1	1	1	1	
	Estimated vaccine wastage factor	Table 4	#	2.00	2.00	1.67	1.67	
	Vaccine stock on 31st December 2013 * (see explanation footnote)		#	197,000				
	Vaccine stock on 1 January 2014 ** (see explanation footnote)		#	197,000				
	Number of doses per vial	Parameter	#		10	10	10	
	AD syringes required	Parameter	#		Yes	Yes	Yes	
	Reconstitution syringes required	Parameter	#		Yes	Yes	Yes	
	Safety boxes required	Parameter	#		Yes	Yes	Yes	
cc	Country co-financing per dose	Co-financing table	\$		0.00	0.00	0.00	
ca	AD syringe price per unit	Table 7.10.1	\$		0.0450	0.0450	0.0450	
cr	Reconstitution syringe price per unit	Table 7.10.1	\$		0	0	0	
cs	Safety box price per unit	Table 7.10.1	\$		0.0050	0.0050	0.0050	
fv	Freight cost as % of vaccines value	Table 7.10.2	%		14.00 %	14.00 %	14.00 %	
fd	Freight cost as % of devices value	Parameter	%		10.00 %	10.00 %	10.00 %	

* Vaccine stock on 31st December 2012: Countries are asked to report their total closing stock as of 31st December of the reporting year.

** Countries are requested to provide their opening stock for 1st January 2014; if there is a difference between the stock on 31st December 2013 and 1st January 2014, please explain why in the box below.

N/A

Co-financing tables for Measles second dose, 10 dose(s) per vial, LYOPHILISED

Co-financing group	Low
--------------------	-----

	2013	2014	2015	2016
Minimum co-financing			0.00	0.00
Recommended co-financing as per APR 2012			0.00	0.00
Your co-financing		0.00		

Table 7.11.2: Estimated GAVI support and country co-financing (GAVI support)

		2014	2015	2016
Number of vaccine doses	#	14,106,600	4,964,600	5,810,100
Number of AD syringes	#	8,465,100	2,940,200	3,835,700
Number of re-constitution syringes	#	1,551,800	546,200	639,200
Number of safety boxes	#	110,200	38,350	49,225
Total value to be co-financed by GAVI	\$	4,366,500	1,614,500	1,968,500

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2014	2015	2016
Number of vaccine doses	#	0	0	0
Number of AD syringes	#	0	0	0
Number of re-constitution syringes	#	0	0	0
Number of safety boxes	#	0	0	0
Total value to be co-financed by the Country	\$	0	0	0

Table 7.11.4: Calculation of requirements for **Measles second dose, 10 dose(s) per vial, LYOPHILISED** (part 1)

	Formula	2013	2014		
			Total	Government	GAVI
A	Country co-finance	V	0.00 %	0.00 %	
B	Number of children to be vaccinated with the first dose	Table 4	3,448,428	6,411,121	0
C	Number of doses per child	Vaccine parameter (schedule)	1	1	
D	Number of doses needed	$B \times C$	3,448,428	6,411,121	0
E	Estimated vaccine wastage factor	Table 4	2.00	2.00	
F	Number of doses needed including wastage	$D \times E$		12,822,242	0
G	Vaccines buffer stock	$((D - D \text{ of previous year}) \times 0.25) + (((D \times E - D) - (D \text{ of previous year} \times E \text{ of previous year} - D \text{ of previous year})) \times 0.25)$		1,481,347	0
H	Stock to be deducted	$H2 \text{ of previous year} - 0.25 \times F \text{ of previous year}$			
H2	Reported stock on January 1st	Table 7.11.1	0		
I	Total vaccine doses needed	$\text{Round up}((F + G - H) / \text{vaccine package size}) \times \text{vaccine package size}$		14,106,600	0
J	Number of doses per vial	Vaccine Parameter		10	
K	Number of AD syringes (+ 10% wastage) needed	$(D + G - H) \times 1.10$		8,465,015	0
L	Reconstitution syringes (+ 10% wastage) needed	$(I / J) \times 1.10$		1,551,727	0
M	Total of safety boxes (+ 10% of extra need) needed	$(K + L) / 100 \times 1.10$		110,185	0
N	Cost of vaccines needed	$I \times \text{vaccine price per dose (g)}$		3,456,117	0
O	Cost of AD syringes needed	$K \times \text{AD syringe price per unit (ca)}$		380,926	0
P	Cost of reconstitution syringes needed	$L \times \text{reconstitution price per unit (cr)}$		6,207	0
Q	Cost of safety boxes needed	$M \times \text{safety box price per unit (cs)}$		551	0
R	Freight cost for vaccines needed	$N \times \text{freight cost as of \% of vaccines value (fv)}$		483,857	0
S	Freight cost for devices needed	$(O+P+Q) \times \text{freight cost as \% of devices value (fd)}$		38,769	0
T	Total fund needed	$(N+O+P+Q+R+S)$		4,366,427	0
U	Total country co-financing	$I \times \text{country co-financing per dose (cc)}$		0	
V	Country co-financing % of GAVI supported proportion	$U / (N + R)$		0.00 %	

Table 7.11.4: Calculation of requirements for Measles second dose, 10 dose(s) per vial, LYOPHILISED (part 2)

	Formula	2015			2016			
		Total	Government	GAVI	Total	Government	GAVI	
A	Country co-finance	V	0.00 %		0.00 %			
B	Number of children to be vaccinated with the first dose	Table 4	3,420,502	0	3,420,502	3,467,363	0	3,467,363
C	Number of doses per child	Vaccine parameter (schedule)	1			1		
D	Number of doses needed	$B \times C$	3,420,502	0	3,420,502	3,467,363	0	3,467,363
E	Estimated vaccine wastage factor	Table 4	1.67			1.67		
F	Number of doses needed including wastage	$D \times E$	5,712,239	0	5,712,239	5,790,497	0	5,790,497
G	Vaccines buffer stock	$((D - D \text{ of previous year}) \times 0.25) + (((D \times E - D) - (D \text{ of previous year} \times E \text{ of previous year} - D \text{ of previous year})) \times 0.25)$	- 747,654	0	- 747,654	19,565	0	19,565
H	Stock to be deducted	$H2 \text{ of previous year} - 0.25 \times F \text{ of previous year}$	0	0	0	0	0	0
H2	Reported stock on January 1st	Table 7.11.1						
I	Total vaccine doses needed	$\text{Round up}((F + G - H) / \text{vaccine package size}) \times \text{vaccine package size}$	4,964,600	0	4,964,600	5,810,100	0	5,810,100
J	Number of doses per vial	Vaccine Parameter	10			10		
K	Number of AD syringes (+ 10% wastage) needed	$(D + G - H) \times 1.10$	2,940,133	0	2,940,133	3,835,621	0	3,835,621
L	Reconstitution syringes (+ 10% wastage) needed	$(I / J) \times 1.10$	546,106	0	546,106	639,111	0	639,111
M	Total of safety boxes (+ 10% of extra need) needed	$(K + L) / 100 \times 1.10$	38,349	0	38,349	49,223	0	49,223
N	Cost of vaccines needed	$I \times \text{vaccine price per dose (g)}$	1,285,832	0	1,285,832	1,557,107	0	1,557,107
O	Cost of AD syringes needed	$K \times \text{AD syringe price per unit (ca)}$	132,306	0	132,306	172,603	0	172,603
P	Cost of reconstitution syringes needed	$L \times \text{reconstitution price per unit (cr)}$	2,185	0	2,185	2,557	0	2,557
Q	Cost of safety boxes needed	$M \times \text{safety box price per unit (cs)}$	192	0	192	247	0	247
R	Freight cost for vaccines needed	$N \times \text{freight cost as of \% of vaccines value (fv)}$	180,017	0	180,017	217,995	0	217,995
S	Freight cost for devices needed	$(O+P+Q) \times \text{freight cost as \% of devices value (fd)}$	13,469	0	13,469	17,541	0	17,541
T	Total fund needed	$(N+O+P+Q+R+S)$	1,614,001	0	1,614,001	1,968,050	0	1,968,050
U	Total country co-financing	$I \times \text{country co-financing per dose (cc)}$	0			0		
V	Country co-financing % of GAVI supported proportion	$U / (N + R)$	0.00 %			0.00 %		

Table 7.11.1: Specifications for Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID

ID	Source		2013	2014	2015	2016	TOTAL
	Number of surviving infants	Table 4	# 3,328,672	3,374,275	3,420,502	3,467,363	13,590,812
	Number of children to be vaccinated with the first dose	Table 4	# 0	6,996,860	0	0	6,996,860
	Number of children to be vaccinated with the third dose	Table 4	#	6,996,860	0	0	6,996,860
	Immunisation coverage with the third dose	Table 4	% 0.00 %	207.36 %	0.00 %	0.00 %	
	Number of doses per child	Parameter	# 3	3	3	3	
	Estimated vaccine wastage factor	Table 4	# 1.00	1.11	1.00	1.00	
	Vaccine stock on 31st December 2013 * (see explanation footnote)		# 0				
	Vaccine stock on 1 January 2014 ** (see explanation footnote)		# 0				
	Number of doses per vial	Parameter	#	2	2	2	
	AD syringes required	Parameter	#	Yes	Yes	Yes	
	Reconstitution syringes required	Parameter	#	No	No	No	
	Safety boxes required	Parameter	#	Yes	Yes	Yes	
cc	Country co-financing per dose	Co-financing table	\$	0.20	0.20	0.20	
ca	AD syringe price per unit	Table 7.10.1	\$	0.0450	0.0450	0.0450	
cr	Reconstitution syringe price per unit	Table 7.10.1	\$	0	0	0	
cs	Safety box price per unit	Table 7.10.1	\$	0.0050	0.0050	0.0050	
fv	Freight cost as % of vaccines value	Table 7.10.2	%	3.00 %	3.00 %	3.00 %	
fd	Freight cost as % of devices value	Parameter	%	0.00 %	0.00 %	0.00 %	

* Vaccine stock on 31st December 2012: Countries are asked to report their total closing stock as of 31st December of the reporting year.

** Countries are requested to provide their opening stock for 1st January 2014; if there is a difference between the stock on 31st December 2013 and 1st January 2014, please explain why in the box below.

N/A

Co-financing tables for Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID

Co-financing group	Low
--------------------	-----

	2013	2014	2015	2016
Minimum co-financing	0.00	0.20	0.20	0.20
Your co-financing		0.20	0.20	0.20

Table 7.11.2: Estimated GAVI support and country co-financing (GAVI support)

		2014	2015	2016
Number of vaccine doses	#	27,457,100	- 4,945,200	0
Number of AD syringes	#	29,497,100	- 5,772,400	0
Number of re-constitution syringes	#	0	0	0
Number of safety boxes	#	324,475	- 63,475	0
Total value to be co-financed by GAVI	\$	97,229,500	- 18,475,000	0

Table 7.11.3: Estimated GAVI support and country co-financing (Country support)

		2014	2015	2016
Number of vaccine doses	#	1,667,800	- 302,300	0
Number of AD syringes	#	0	0	0
Number of re-constitution syringes	#	0	0	0
Number of safety boxes	#	0	0	0
Total value to be co-financed by the Country	\$	5,825,000	0	0

Table 7.11.4: Calculation of requirements for Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID (part 1)

	Formula	2013	2014			
			Total	Government	GAVI	
A	Country co-finance	V	0.00 %	5.73 %		
B	Number of children to be vaccinated with the first dose	Table 4	0	6,996,860	400,653	6,596,207
C	Number of doses per child	Vaccine parameter (schedule)	3	3		
D	Number of doses needed	$B \times C$	0	20,990,580	1,201,959	19,788,621
E	Estimated vaccine wastage factor	Table 4	1.00	1.11		
F	Number of doses needed including wastage	$D \times E$		23,299,544	1,334,174	21,965,370
G	Vaccines buffer stock	$((D - D \text{ of previous year}) \times 0.25) + (((D \times E - D) - (D \text{ of previous year} \times E \text{ of previous year} - D \text{ of previous year})) \times 0.25)$		5,824,886	333,544	5,491,342
H	Stock to be deducted	$H2 \text{ of previous year} - 0.25 \times F \text{ of previous year}$				
H2	Reported stock on January 1st	Table 7.11.1	0			
I	Total vaccine doses needed	$\text{Round up}((F + G - H) / \text{vaccine package size}) \times \text{vaccine package size}$		29,124,800	1,667,739	27,457,061
J	Number of doses per vial	Vaccine Parameter		2		
K	Number of AD syringes (+ 10% wastage) needed	$(D + G - H) \times 1.10$		29,497,013	0	29,497,013
L	Reconstitution syringes (+ 10% wastage) needed	$(I / J) \times 1.10$		0	0	0
M	Total of safety boxes (+ 10% of extra need) needed	$(K + L) / 100 \times 1.10$		324,468	0	324,468
N	Cost of vaccines needed	$I \times \text{vaccine price per dose (g)}$		98,762,197	5,655,301	93,106,896
O	Cost of AD syringes needed	$K \times \text{AD syringe price per unit (ca)}$		1,327,366	0	1,327,366
P	Cost of reconstitution syringes needed	$L \times \text{reconstitution price per unit (cr)}$		0	0	0
Q	Cost of safety boxes needed	$M \times \text{safety box price per unit (cs)}$		1,623	0	1,623
R	Freight cost for vaccines needed	$N \times \text{freight cost as of \% of vaccines value (fv)}$		2,962,866	169,660	2,793,206
S	Freight cost for devices needed	$(O+P+Q) \times \text{freight cost as \% of devices value (fd)}$		0	0	0
T	Total fund needed	$(N+O+P+Q+R+S)$		103,054,052	5,824,960	97,229,092
U	Total country co-financing	$I \times \text{country co-financing per dose (cc)}$		5,824,960		
V	Country co-financing % of GAVI supported proportion	$U / (N + R)$		5.73 %		

Table 7.11.4: Calculation of requirements for Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID (part 2)

	Formula	2015			2016			
		Total	Government	GAVI	Total	Government	GAVI	
A	Country co-finance	V	5.76 %			0.00 %		
B	Number of children to be vaccinated with the first dose	Table 4	0	0	0	0	0	0
C	Number of doses per child	Vaccine parameter (schedule)	3			3		
D	Number of doses needed	$B \times C$	0	0	0	0	0	0
E	Estimated vaccine wastage factor	Table 4	1.00			1.00		
F	Number of doses needed including wastage	$D \times E$	0	0	0	0	0	0
G	Vaccines buffer stock	$((D - D \text{ of previous year}) \times 0.25) + (((D \times E - D) - (D \text{ of previous year} \times E \text{ of previous year} - D \text{ of previous year})) \times 0.25)$	- 5,247,645	- 302,362	- 4,945,283	0	0	0
H	Stock to be deducted	$H2 \text{ of previous year} - 0.25 \times F \text{ of previous year}$	0	0	0	0	0	0
H2	Reported stock on January 1st	Table 7.11.1						
I	Total vaccine doses needed	$\text{Round up}((F + G - H) / \text{vaccine package size}) \times \text{vaccine package size}$	- 5,247,600	- 302,359	- 4,945,241	0	0	0
J	Number of doses per vial	Vaccine Parameter	2			2		
K	Number of AD syringes (+ 10% wastage) needed	$(D + G - H) \times 1.10$	- 5,772,409	0	- 5,772,409	0	0	0
L	Reconstitution syringes (+ 10% wastage) needed	$(I / J) \times 1.10$	0	0	0	0	0	0
M	Total of safety boxes (+ 10% of extra need) needed	$(K + L) / 100 \times 1.10$	- 63,496	0	- 63,496	0	0	0
N	Cost of vaccines needed	$I \times \text{vaccine price per dose (g)}$	- 17,684,412	- 1,018,951	- 16,665,461	0	0	0
O	Cost of AD syringes needed	$K \times \text{AD syringe price per unit (ca)}$	- 259,758	0	- 259,758	0	0	0
P	Cost of reconstitution syringes needed	$L \times \text{reconstitution price per unit (cr)}$	0	0	0	0	0	0
Q	Cost of safety boxes needed	$M \times \text{safety box price per unit (cs)}$	- 317	0	- 317	0	0	0
R	Freight cost for vaccines needed	$N \times \text{freight cost as of \% of vaccines value (fv)}$	- 530,532	- 30,568	- 499,964	0	0	0
S	Freight cost for devices needed	$(O+P+Q) \times \text{freight cost as \% of devices value (fd)}$	0	0	0	0	0	0
T	Total fund needed	$(N+O+P+Q+R+S)$	- 18,475,019	0	- 18,475,019	0	0	0
U	Total country co-financing	$I \times \text{country co-financing per dose (cc)}$	- 1,049,520			0		
V	Country co-financing % of GAVI supported proportion	$U / (N + R)$	5.76 %			0.00 %		

8. Injection Safety Support (INS)

This window of support is no longer available

9. Health Systems Strengthening Support (HSS)

Instructions for reporting on HSS funds received

1. Please complete this section only if your country **was approved for and received HSS funds before or during January to December 2013**. All countries are expected to report on:

- a. Progress achieved in 2013
- b. HSS implementation during January – April 2014 (interim reporting)
- c. Plans for 2015
- d. Proposed changes to approved activities and budget (see No. 4 below)

For countries that received HSS funds within the last 3 months of 2013, or experienced other delays that limited implementation in 2013, this section can be used as an inception report to comment on start up activities.

2. In order to better align HSS support reporting to country processes, for countries of which the 2013 fiscal year starts in January 2013 and ends in December 2013, HSS reports should be received by the GAVI Alliance before **15th May 2014**. For other countries, HSS reports should be received by the GAVI Alliance approximately six months after the end of country fiscal year, e.g., if the country fiscal year ends in March 2014, the HSS reports are expected by GAVI Alliance by September 2014.

3. Please use your approved proposal as reference to fill in this Annual Progress Report. Please fill in this reporting template thoroughly and accurately and use additional space as necessary.

4. If you are proposing changes to approved objectives, activities and budget (reprogramming) please request the reprogramming guidelines by contacting your Country Responsible Officer at GAVI or by emailing gavihss@gavialliance.org.

5. If you are requesting a new tranche of funding, please make this clear in [Section 9.1.2](#).

6. Please ensure that, **prior to its submission to the GAVI Alliance Secretariat, this report has been endorsed by the relevant country coordination mechanisms** (HSCC or equivalent) [as provided for on the signature page](#) in terms of its accuracy and validity of facts, figures and sources used.

7. Please attach all required [supporting documents](#). These include:

- a. Minutes of all the HSCC meetings held in 2013
- b. Minutes of the HSCC meeting in 2014 that endorses the submission of this report
- c. Latest Health Sector Review Report
- d. Financial statement for the use of HSS funds in the 2013 calendar year
- e. External audit report for HSS funds during the most recent fiscal year (if available)

8. The GAVI Alliance Independent Review Committee (IRC) reviews all Annual Progress Reports. In addition to the information listed above, the IRC requires the following information to be included in this section in order to approve further tranches of HSS funding:

- a. Reporting on agreed indicators, as outlined in the approved M&E framework, proposal and approval letter;
- b. Demonstration of (with tangible evidence) strong links between activities, output, outcome and impact indicators;
- c. Outline of technical support that may be required to either support the implementation or monitoring of the GAVI HSS investment in the coming year

9. Inaccurate, incomplete or unsubstantiated reporting may lead the IRC to either send the APR back to your country for clarifications (which may cause delays in the release of further HSS funds), to recommend against the release of further HSS funds or only approve part of the next tranche of HSS funds.

9.1. Report on the use of HSS funds in 2013 and request of a new tranche

For countries that have previously received the final disbursement of all GAVI approved funds for the HSS grant and have no further funds to request: Is the implementation of the HSS grant completed ? **Yes**

If NO, please indicate the anticipated date for completion of the HSS grant.

Please attach any studies or assessments related to or funded by the GAVI HSS grant.

Please attach data disaggregated by sex, rural/urban, district/state where available, particularly for immunisation coverage indicators. This is especially important if GAVI HSS grants are used to target specific populations and/or geographic areas in the country.

If CSOs were involved in the implementation of the HSS grant, please attach a list of the CSOs engaged in grant implementation, the funding received by CSOs from the GAVI HSS grant, and the activities that they have been involved in. If CSO involvement was included in the original proposal approved by GAVI but no funds were provided to CSOs, please explain why not.

NA

Please see <http://www.gavialliance.org/support/cso/> for GAVI's CSO Implementation Framework

Please provide data sources for all data used in this report.

Please attach the latest reported National Results/M&E Framework for the health sector (with actual reported figures for the most recent year available in country).

9.1.1. Report on the use of HSS funds in **2013**

Please complete [Table 9.1.3.a](#) and [9.1.3.b](#) (as per APR) for each year of your country's approved multi-year HSS programme and both in US\$ and local currency

Please note: If you are requesting a new tranche of funding, please make sure you fill in the last row of [Table 9.1.3.a](#) and [9.1.3.b](#).

9.1.2. Please indicate if you are requesting a new tranche of funding **No**

If yes, please indicate the amount of funding requested: US\$

These funds should be sufficient to carry out HSS grant implementation through December 2015.

9.1.3. Is GAVI's HSS support reported on the national health sector budget? **Not selected**

NB: Country will fill both \$ and local currency tables. This enables consistency check for TAP.

Table 9.1.3a (US)\$

	2008	2009	2010	2011	2012	2013
Original annual budgets (as per the originally approved HSS proposal)						
Revised annual budgets (if revised by previous Annual Progress Reviews)						
Total funds received from GAVI during the calendar year (A)						

Remaining funds (carry over) from previous year (<i>B</i>)						
Total Funds available during the calendar year ($C=A+B$)						
Total expenditure during the calendar year (<i>D</i>)						
Balance carried forward to next calendar year ($E=C-D$)						
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]						

	2014	2015	2016	2017
Original annual budgets (as per the originally approved HSS proposal)				
Revised annual budgets (if revised by previous Annual Progress Reviews)				
Total funds received from GAVI during the calendar year (A)				
Remaining funds (carry over) from previous year (B)				
Total Funds available during the calendar year (C=A+B)				
Total expenditure during the calendar year (D)				
Balance carried forward to next calendar year (E=C-D)				
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]				

Table 9.1.3b (Local currency)

	2008	2009	2010	2011	2012	2013
Original annual budgets (as per the originally approved HSS proposal)						
Revised annual budgets (if revised by previous Annual Progress Reviews)						
Total funds received from GAVI during the calendar year (A)						
Remaining funds (carry over) from previous year (B)						
Total Funds available during the calendar year (C=A+B)						
Total expenditure during the calendar year (D)						
Balance carried forward to next calendar year (E=C-D)						
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]						

	2014	2015	2016	2017
Original annual budgets (as per the originally approved HSS proposal)				
Revised annual budgets (if revised by previous Annual Progress Reviews)				
Total funds received from GAVI during the calendar year (A)				
Remaining funds (carry over) from previous year (B)				
Total Funds available during the calendar year (C=A+B)				
Total expenditure during the calendar year (D)				
Balance carried forward to next calendar year (E=C-D)				
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]				

Report of Exchange Rate Fluctuation

Please indicate in the table [Table 9.3.c](#) below the exchange rate used for each calendar year at opening and closing.

[Table 9.1.3.c](#)

Exchange Rate	2008	2009	2010	2011	2012	2013
Opening on 1 January						
Closing on 31 December						

Detailed expenditure of HSS funds during the 2013 calendar year

Please attach a detailed financial statement for the use of HSS funds during the 2013 calendar year (*Terms of reference for this financial statement are attached in the online APR Annexes*). Financial statements should be signed by the Chief Accountant or by the Permanent Secretary of Ministry of Health. **(Document Number: 19)**

If any expenditures for the January April 2014 period are reported in Tables 9.1.3a and 9.1.3b, a separate, detailed financial statement for the use of these HSS funds must also be attached **(Document Number: 20)**

Financial management of HSS funds

Briefly describe the financial management arrangements and process used for your HSS funds. Notify whether HSS funds have been included in national health sector plans and budgets. Report also on any problems that have been encountered involving the use of HSS funds, such as delays in availability of funds for programme use.

Please include details on: the type of bank account(s) used (commercial versus government accounts); how budgets are approved; how funds are channelled to the sub-national levels; financial reporting arrangements

at both the sub-national and national levels; and the overall role of the HSCC in this process.

Has an external audit been conducted? **Not selected**

External audit reports for HSS programmes are due to the GAVI Secretariat six months following the close of your governments fiscal year. If an external audit report is available during your governments most recent fiscal year, this must also be attached (Document Number: 21)

9.2. Progress on HSS activities in the 2013 fiscal year

Please report on major activities conducted to strengthen immunisation using HSS funds in Table 9.2. It is very important to be precise about the extent of progress and use the M&E framework in your original application and approval letter.

Please provide the following information for each planned activity:

- The percentage of activity completed where applicable
- An explanation about progress achieved and constraints, if any
- The source of information/data if relevant.

Table 9.2: HSS activities in the 2013 reporting year

Major Activities (insert as many rows as necessary)	Planned Activity for 2013	Percentage of Activity completed (annual) (where applicable)	Source of information/data (if relevant)
---	---------------------------	--	--

9.2.1 For each objective and activity (i.e. Objective 1, Activity 1.1, Activity 1.2, etc.), explain the progress achieved and relevant constraints (e.g. evaluations, HSCC meetings).

Major Activities (insert as many rows as necessary)	Explain progress achieved and relevant constraints
---	--

9.2.2 Explain why any activities have not been implemented, or have been modified, with references.

9.2.3 If GAVI HSS grant has been utilised to provide national health human resources incentives, how has the GAVI HSS grant been contributing to the implementation of national Human Resource policy or guidelines?

9.3. General overview of targets achieved

Please complete **Table 9.3** for each indicator and objective outlined in the original approved proposal and decision letter. Please use the baseline values and targets for 2012 from your original HSS proposal.

Table 9.3: Progress on targets achieved

Name of Objective or Indicator (Insert as many rows as necessary)	Baseline		Agreed target till end of support in original HSS application	2013 Target	Data Source	Explanation if any targets were not achieved
	Baseline value	Baseline source/date				

9.4. Programme implementation in 2013

9.4.1. Please provide a narrative on major accomplishments in 2013, especially impacts on health service programmes, and how the HSS funds benefited the immunisation programme

9.4.2. Please describe problems encountered and solutions found or proposed to improve future performance of HSS funds.

9.4.3. Please describe the exact arrangements at different levels for monitoring and evaluating GAVI funded HSS activities.

9.4.4. Please outline to what extent the M&E is integrated with country systems (such as, for example, annual sector reviews). Please describe ways in which reporting on GAVI HSS funds can be more organization with existing reporting systems in your country. This could include using the relevant indicators agreed in the sector-wide approach in place of GAVI indicators.

9.4.5. Please specify the participation of key stakeholders in the implementation of the HSS proposal (including the EPI Programme and Civil Society Organisations). This should include organisation type, name and implementation function.

9.4.6. Please describe the participation of Civil Society Organisations in the implementation of the HSS proposal. Please provide names of organisations, type of activities and funding provided to these organisations from the HSS funding.

9.4.7. Please describe the management of HSS funds and include the following:

- Whether the management of HSS funds has been effective
- Constraints to internal fund disbursement, if any
- Actions taken to address any issues and to improve management
- Any changes to management processes in the coming year

9.5. Planned HSS activities for 2014

Please use **Table 9.5** to provide information on progress on activities in 2014. If you are proposing changes to your activities and budget in 2014 please explain these changes in the table below and provide explanations for these changes.

Table 9.5: Planned activities for 2014

Major Activities (insert as many rows as necessary)	Planned Activity for 2014	Original budget for 2014 (as approved in the HSS proposal or as adjusted during past annual progress reviews)	2014 actual expenditure (as at April 2014)	Revised activity (if relevant)	Explanation for proposed changes to activities or budget (if relevant)	Revised budget for 2014 (if relevant)
		0	0			0

9.6. Planned HSS activities for 2015

Please use **Table 9.6** to outline planned activities for 2015. If you are proposing changes to your activities and budget please explain these changes in the table below and provide explanations for each change so that the IRC can recommend for approval the revised budget and activities.

Please note that if the change in budget is greater than 15% of the approved allocation for the specific activity in that financial year, these proposed changes must be submitted for IRC approval with the evidence for requested changes

Table 9.6: Planned HSS Activities for 2015

Major Activities (insert as many rows as necessary)	Planned Activity for 2015	Original budget for 2015 (as approved in the HSS proposal or as adjusted during past annual progress reviews)	Revised activity (if relevant)	Explanation for proposed changes to activities or budget (if relevant)	Revised budget for 2015 (if relevant)
		0			

9.7. Revised indicators in case of reprogramming

Countries planning to submit reprogramming requests may do so any time of the year. Please request the reprogramming guidelines by contacting your Country Responsible Officer at GAVI or by emailing gavihss@gavialliance.org

9.8. Other sources of funding for HSS

If other donors are contributing to the achievement of the country's objectives as outlined in the GAVI HSS proposal, please outline the amount and links to inputs being reported on:

Table 9.8: Sources of HSS funds in your country

Donor	Amount in US\$	Duration of support	Type of activities funded

9.8.1. Is GAVI's HSS support reported on the national health sector budget? **No**

9.9. Reporting on the HSS grant

9.9.1. Please list the **main** sources of information used in this HSS report and outline the following:

- How information was validated at country level prior to its submission to the GAVI Alliance.
- Any important issues raised in terms of accuracy or validity of information (especially financial information and the values of indicators) and how these were dealt with or resolved.

Table 9.9: Data sources

Data sources used in this report	How information was validated	Problems experienced, if any

9.9.2. Please describe any difficulties experienced in putting this report together that you would like the GAVI Alliance and IRC to be aware of. This information will be used to improve the reporting process.

9.9.3. How many times did the Health Sector Coordinating Committee (HSCC) meet in 2013?

Please attach:

1. The minutes from the HSCC meetings in 2014 endorsing this report (**Document Number: 6**)
2. The latest Health Sector Review report (**Document Number: 22**)

10. Strengthened Involvement of Civil Society Organisations (CSOs) : Type A and Type B

10.1. TYPE A: Support to strengthen coordination and representation of CSOs

Bangladesh **has NOT received GAVI TYPE A CSO support**

Bangladesh is not reporting on GAVI TYPE A CSO support for 2013


10.2. TYPE B: Support for CSOs to help implement the GAVI HSS proposal or cMYP

Bangladesh **has NOT received GAVI TYPE B CSO support**

Bangladesh is not reporting on GAVI TYPE B CSO support for 2013

11. Comments from ICC/HSCC Chairs

Please provide any comments that you may wish to bring to the attention of the monitoring IRC in the course of this review and any information you may wish to share in relation to challenges you have experienced during the year under review. These could be in addition to the approved minutes, which should be included in the attachments



12. Annexes

12.1. Annex 1 – Terms of reference ISS

TERMS OF REFERENCE:

FINANCIAL STATEMENTS FOR IMMUNISATION SERVICES SUPPORT (ISS) AND NEW VACCINE INTRODUCTION GRANTS

- I. All countries that have received ISS /new vaccine introduction grants during the 2013 calendar year, or had balances of funding remaining from previously disbursed ISS/new vaccine introduction grants in 2013, are required to submit financial statements for these programmes as part of their Annual Progress Reports.
- II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.
- III. **At a minimum**, GAVI requires a simple statement of income and expenditure for activity during the 2013 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on the next page.
- a. Funds carried forward from the 2012 calendar year (opening balance as of 1 January 2013)
 - b. Income received from GAVI during 2013
 - c. Other income received during 2013 (interest, fees, etc)
 - d. Total expenditure during the calendar year
 - e. Closing balance as of 31 December 2013
 - f. A detailed analysis of expenditures during 2013, based on **your government's own system of economic classification**. This analysis should summarise total annual expenditure for the year by your government's own system of economic classification, and relevant cost categories, for example: wages & salaries. If possible, please report on the budget for each category at the beginning of the calendar year, actual expenditure during the calendar year, and the balance remaining for each cost category as of 31 December 2013 (referred to as the "variance").
- IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.
- V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2013 financial year. Audits for ISS are due to the GAVI Secretariat 6 months following the close of each country's financial year.

12.2. Annex 2 – Example income & expenditure ISS

MINIMUM REQUIREMENTS FOR ISS AND VACCINE INTRODUCTION GRANT FINANCIAL STATEMENTS

1

An example statement of income & expenditure

Summary of income and expenditure – GAVI ISS		
	Local currency (CFA)	Value in USD *
Balance brought forward from 2012 (balance as of 31Decembre 2012)	25,392,830	53,000
Summary of income received during 2013		
Income received from GAVI	57,493,200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2013	30,592,132	63,852
Balance as of 31 December 2013 (balance carried forward to 2014)	60,139,325	125,523

* Indicate the exchange rate at opening 01.01.2013, the exchange rate at closing 31.12.2013, and also indicate the exchange rate used for the conversion of local currency to US\$ in these financial statements.

Detailed analysis of expenditure by economic classification ** – GAVI ISS						
	Budget in CFA	Budget in USD	Actual in CFA	Actual in USD	Variance in CFA	Variance in USD
Salary expenditure						
Wages & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12,650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4,000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1,000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2013	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

12.3. Annex 3 – Terms of reference HSS

TERMS OF REFERENCE:

FINANCIAL STATEMENTS FOR **HEALTH SYSTEMS STRENGTHENING (HSS)**

- I. All countries that have received HSS grants during the 2013 calendar year, or had balances of funding remaining from previously disbursed HSS grants in 2013, are required to submit financial statements for these programmes as part of their Annual Progress Reports.
- II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.
- III. At a minimum, GAVI requires a simple statement of income and expenditure for activity during the 2013 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on the next page.
 - a. Funds carried forward from the 2012 calendar year (opening balance as of 1 January 2013)
 - b. Income received from GAVI during 2013
 - c. Other income received during 2013 (interest, fees, etc)
 - d. Total expenditure during the calendar year
 - e. Closing balance as of 31 December 2013
 - f. A detailed analysis of expenditures during 2013, based on your government's own system of economic classification. This analysis should summarise total annual expenditure for each HSS objective and activity, per your government's originally approved HSS proposal, with further breakdown by cost category (for example: wages & salaries). Cost categories used should be based upon your government's own system for economic classification. Please report the budget for each objective, activity and cost category at the beginning of the calendar year, the actual expenditure during the calendar year, and the balance remaining for each objective, activity and cost category as of 31 December 2013 (referred to as the "variance").
- IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.
- V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2013 financial year. Audits for HSS are due to the GAVI Secretariat 6 months following the close of each country's financial year.

12.4. Annex 4 – Example income & expenditure HSS

MINIMUM REQUIREMENTS FOR HSS FINANCIAL STATEMENTS:

An example statement of income & expenditure

Summary of income and expenditure – GAVI HSS		
	Local currency (CFA)	Value in USD *
Balance brought forward from 2012 (balance as of 31Decembre 2012)	25,392,830	53,000
Summary of income received during 2013		
Income received from GAVI	57,493,200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2013	30,592,132	63,852
Balance as of 31 December 2013 (balance carried forward to 2014)	60,139,325	125,523

* Indicate the exchange rate at opening 01.01.2013, the exchange rate at closing 31.12.2013, and also indicate the exchange rate used for the conversion of local currency to US\$ in these financial statements.

Detailed analysis of expenditure by economic classification ** - GAVI HSS						
	Budget in CFA	Budget in USD	Actual in CFA	Actual in USD	Variance in CFA	Variance in USD
Salary expenditure						
Wages & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12,650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4,000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1,000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2013	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

12.5. Annex 5 – Terms of reference CSO

TERMS OF REFERENCE:

FINANCIAL STATEMENTS FOR **CIVIL SOCIETY ORGANISATION (CSO)** TYPE B

- I. All countries that have received CSO 'Type B' grants during the 2013 calendar year, or had balances of funding remaining from previously disbursed CSO 'Type B' grants in 2013, are required to submit financial statements for these programmes as part of their Annual Progress Reports.
- II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.
- III. At a minimum, GAVI requires a simple statement of income and expenditure for activity during the 2013 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on page 3 of this annex.
 - a. Funds carried forward from the 2012 calendar year (opening balance as of 1 January 2013)
 - b. Income received from GAVI during 2013
 - c. Other income received during 2013 (interest, fees, etc)
 - d. Total expenditure during the calendar year
 - e. Closing balance as of 31 December 2013
 - f. A detailed analysis of expenditures during 2013, based on your government's own system of economic classification. This analysis should summarise total annual expenditure by each civil society partner, per your government's originally approved CSO 'Type B' proposal, with further breakdown by cost category (for example: wages & salaries). Cost categories used should be based upon your government's own system for economic classification. Please report the budget for each objective, activity and cost category at the beginning of the calendar year, the actual expenditure during the calendar year, and the balance remaining for each objective, activity and cost category as of 31 December 2013 (referred to as the "variance").
- IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.
- V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2013 financial year. Audits for CSO 'Type B' are due to the GAVI Secretariat 6 months following the close of each country's financial year.

12.6. Annex 6 – Example income & expenditure CSO

MINIMUM REQUIREMENTS FOR CSO 'Type B' FINANCIAL STATEMENTS

An example statement of income & expenditure

Summary of income and expenditure – GAVI CSO		
	Local currency (CFA)	Value in USD *
Balance brought forward from 2012 (balance as of 31Decembre 2012)	25,392,830	53,000
Summary of income received during 2013		
Income received from GAVI	57,493,200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2013	30,592,132	63,852
Balance as of 31 December 2013 (balance carried forward to 2014)	60,139,325	125,523

* Indicate the exchange rate at opening 01.01.2013, the exchange rate at closing 31.12.2013, and also indicate the exchange rate used for the conversion of local currency to US\$ in these financial statements.

Detailed analysis of expenditure by economic classification ** - GAVI CSO						
	Budget in CFA	Budget in USD	Actual in CFA	Actual in USD	Variance in CFA	Variance in USD
Salary expenditure						
Wages & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12,650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4,000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1,000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2013	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

13. Attachments

Document Number	Document	Section	Mandatory	File
1	Signature of Minister of Health (or delegated authority)	2.1	✓	signature of Minister of Health.pdf File desc: Date/time : 15/05/2014 04:38:05 Size: 329 KB
2	Signature of Minister of Finance (or delegated authority)	2.1	✓	Signature of Minister of Finance.pdf File desc: Date/time : 15/05/2014 04:39:53 Size: 330 KB
3	Signatures of members of ICC	2.2	✓	Signature of Members of ICC.pdf File desc: Date/time : 15/05/2014 05:43:24 Size: 223 KB
4	Minutes of ICC meeting in 2014 endorsing the APR 2013	5.7	✓	ICC minutes Endorshed APR.pdf File desc: Date/time : 14/05/2014 10:19:04 Size: 2 MB
5	Signatures of members of HSCC	2.3	✓	Not Applicable.pdf File desc: Date/time : 08/05/2014 03:35:54 Size: 4 KB
6	Minutes of HSCC meeting in 2014 endorsing the APR 2013	9.9.3	✓	Not Applicable.pdf File desc: Date/time : 08/05/2014 03:36:48 Size: 4 KB
7	Financial statement for ISS grant (Fiscal year 2013) signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	6.2.1	✗	No file loaded
8	External audit report for ISS grant (Fiscal Year 2013)	6.2.3	✗	No file loaded
9	Post Introduction Evaluation Report	7.2.2	✓	EPI & VPD Surveillance Review Report & PIE_final.pdf File desc: Date/time : 08/05/2014 03:38:03 Size: 1 MB

10	Financial statement for NVS introduction grant (Fiscal year 2013) signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	7.3.1	✓	Financial statement of NVS.pdf File desc: Date/time : 15/05/2014 04:46:47 Size: 364 KB
11	External audit report for NVS introduction grant (Fiscal year 2013) if total expenditures in 2013 is greater than US\$ 250,000	7.3.1	✓	External Audit report for NVS.pdf File desc: Date/time : 15/05/2014 04:48:51 Size: 581 KB
12	Latest EVSM/VMA/EVM report	7.5	✓	EVM Assessment Report and Improvement Plan - Bangladesh 2011.pdf File desc: Date/time : 08/05/2014 03:39:19 Size: 1 MB
13	Latest EVSM/VMA/EVM improvement plan	7.5	✓	EVM Improvement Plan.pdf File desc: Date/time : 08/05/2014 03:40:20 Size: 550 KB
14	EVSM/VMA/EVM improvement plan implementation status	7.5	✓	Status EVM Plan.docx File desc: Date/time : 08/05/2014 04:06:11 Size: 108 KB
16	Valid cMYP if requesting extension of support	7.8	✗	No file loaded
17	Valid cMYP costing tool if requesting extension of support	7.8	✗	No file loaded
18	Minutes of ICC meeting endorsing extension of vaccine support if applicable	7.8	✗	No file loaded
19	Financial statement for HSS grant (Fiscal year 2013) signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	9.1.3	✓	Not Applicable.pdf File desc: Date/time : 08/05/2014 03:41:58 Size: 4 KB

20	Financial statement for HSS grant for January-April 2014 signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	9.1.3	✓	Not Applicable.pdf File desc: Date/time : 08/05/2014 03:42:20 Size: 4 KB
21	External audit report for HSS grant (Fiscal Year 2013)	9.1.3	✓	Not Applicable.pdf File desc: Date/time : 08/05/2014 03:42:44 Size: 4 KB
22	HSS Health Sector review report	9.9.3	✓	Not Applicable.pdf File desc: Date/time : 08/05/2014 03:43:04 Size: 4 KB
23	Report for Mapping Exercise CSO Type A	10.1.1	✗	No file loaded
24	Financial statement for CSO Type B grant (Fiscal year 2013)	10.2.4	✗	No file loaded
25	External audit report for CSO Type B (Fiscal Year 2013)	10.2.4	✗	No file loaded
26	Bank statements for each cash programme or consolidated bank statements for all existing cash programmes if funds are comingled in the same bank account, showing the opening and closing balance for year 2013 on (i) 1st January 2013 and (ii) 31st December 2013	0	✓	Bank statement in BDT and USD.pdf File desc: Date/time : 15/05/2014 04:56:31 Size: 837 KB
27	Minutes ICC meeting endorsing change of vaccine presentation	7.7	✗	No file loaded
	Other		✗	Minutes_40th ICC.pdf File desc: Date/time : 08/05/2014 04:07:12

				Size: 865 KB
				Minutes_41st ICC.pdf File desc: Date/time : 08/05/2014 04:07:57 Size: 2 MB
				Minutes_42 ICC.pdf File desc: Date/time : 08/05/2014 04:08:37 Size: 707 KB